Celldex Therapeutics, Inc.CLDXNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank85
3Y CAGR+47.5%
5Y CAGR-34.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+47.5%/yr
vs -14.2%/yr prior
5Y CAGR
-34.6%/yr
Recent acceleration
Acceleration
+61.7pp
Accelerating
Percentile
P85
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 19.75% |
| Q3 2025 | 16.12% |
| Q2 2025 | 3.01% |
| Q1 2025 | 14.08% |
| Q4 2024 | 1537233.33% |
| Q3 2024 | -99.99% |
| Q2 2024 | 25.91% |
| Q1 2024 | 1.51% |
| Q4 2023 | -11.90% |
| Q3 2023 | 31.55% |
| Q2 2023 | -2.04% |
| Q1 2023 | 17.03% |
| Q4 2022 | 6.15% |
| Q3 2022 | 4.06% |
| Q2 2022 | 21.55% |
| Q1 2022 | 16.20% |
| Q4 2021 | -13.95% |
| Q3 2021 | 38.05% |
| Q2 2021 | -2.86% |
| Q1 2021 | -55.25% |
| Q4 2020 | 165.46% |
| Q3 2020 | -18.91% |
| Q2 2020 | 12.91% |
| Q1 2020 | 13.12% |
| Q4 2019 | -6.86% |
| Q3 2019 | 10.12% |
| Q2 2019 | -9.60% |
| Q1 2019 | -0.50% |
| Q4 2018 | -5.97% |
| Q3 2018 | -44.43% |
| Q2 2018 | -1.95% |
| Q1 2018 | -6.77% |
| Q4 2017 | 7.07% |
| Q3 2017 | -12.34% |
| Q2 2017 | -3.08% |
| Q1 2017 | 5.03% |
| Q4 2016 | -1.80% |
| Q3 2016 | -2.73% |
| Q2 2016 | -6.32% |
| Q1 2016 | 14.84% |